Kidney intercalated cells and the transcription factor FOXi1 drive cystogenesis in tuberous sclerosis complex

Significance Tuberous sclerosis complex (TSC) is caused by mutations in TSC1 or TSC2 gene and affects multiple organs, including the kidney, where it presents with angiomyolipomata and cysts that can result in kidney failure. The factors promoting cyst formation and tumor growth in TSC are incompletely understood. Current studies demonstrate that kidney cyst epithelia in TSC mouse models and in humans with TSC are composed of hyperproliferating intercalated cells, along with activation of H+-ATPase and carbonic anhydrase 2. Interfering with intercalated cell proliferation completely inhibited and inactivating carbonic anhydrase 2 significantly protected against cyst formation in TSC. Targeting the acid base and/or electrolyte transporters of intercalated cells may provide a therapeutic approach for the treatment of kidney cysts in TSC. Tuberous sclerosis complex (TSC) is caused by mutations in either TSC1 or TSC2 genes and affects multiple organs, including kidney, lung, and brain. In the kidney, TSC presents with the enlargement of benign tumors (angiomyolipomata) and cysts, which eventually leads to kidney failure. The factors promoting cyst formation and tumor growth in TSC are incompletely understood. Here, we report that mice with principal cell-specific inactivation of Tsc1 develop numerous cortical cysts, which are overwhelmingly composed of hyperproliferating A-intercalated (A-IC) cells. RNA sequencing and confirmatory expression studies demonstrated robust expression of Forkhead Transcription Factor 1 (Foxi1) and its downstream targets, apical H+-ATPase and cytoplasmic carbonic anhydrase 2 (CAII), in cyst epithelia in Tsc1 knockout (KO) mice but not in Pkd1 mutant mice. In addition, the electrogenic 2Cl−/H+ exchanger (CLC-5) is significantly up-regulated and shows remarkable colocalization with H+-ATPase on the apical membrane of cyst epithelia in Tsc1 KO mice. Deletion of Foxi1, which is vital to intercalated cells viability and H+-ATPase expression, completely abrogated the cyst burden in Tsc1 KO mice, as indicated by MRI images and histological analysis in kidneys of Foxi1/Tsc1 double-knockout (dKO) mice. Deletion of CAII, which is critical to H+-ATPase activation, caused significant reduction in cyst burden and increased life expectancy in CAII/Tsc1 dKO mice vs. Tsc1 KO mice. We propose that intercalated cells and their acid/base/electrolyte transport machinery (H+-ATPase/CAII/CLC-5) are critical to cystogenesis, and their inhibition or inactivation is associated with significant protection against cyst generation and/or enlargement in TSC.

[1]  Ming-Zhi Zhang,et al.  Notch signaling is essential in collecting duct epithelial cell fate determination during development and maintenance of cell type homeostasis in adult. , 2019, Annals of translational medicine.

[2]  B. Siroky,et al.  Tuberous sclerosis complex exhibits a new renal cystogenic mechanism , 2019, Physiological reports.

[3]  Divya Kota,et al.  Endogenous Notch Signaling in Adult Kidneys Maintains Segment-Specific Epithelial Cell Types of the Distal Tubules and Collecting Ducts to Ensure Water Homeostasis. , 2018, Journal of the American Society of Nephrology : JASN.

[4]  Marie E. Edwards,et al.  Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[5]  Pontus Eriksson,et al.  Cell-Type-Specific Gene Programs of the Normal Human Nephron Define Kidney Cancer Subtypes. , 2017, Cell reports.

[6]  J. Peters The (pro)renin receptor and its interaction partners , 2017, Pflügers Archiv - European Journal of Physiology.

[7]  Q. Al-Awqati,et al.  Transcription factor TFCP2L1 patterns cells in the mouse kidney collecting ducts , 2017, eLife.

[8]  F. Reis,et al.  Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex , 2017, Oxidative medicine and cellular longevity.

[9]  P. Ashton-Prolla,et al.  TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review , 2017, Genetics and molecular biology.

[10]  G. Seki,et al.  Functional coupling of V-ATPase and CLC-5 , 2017, World journal of nephrology.

[11]  E. Henske,et al.  New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex , 2017, The Journal of pathology.

[12]  A. Sangoi,et al.  Tuberous sclerosis complex: Hamartin and tuberin expression in renal cysts and its discordant expression in renal neoplasms. , 2016, Pathology, research and practice.

[13]  D. Kohan,et al.  The nephron (pro)renin receptor: function and significance. , 2016, American journal of physiology. Renal physiology.

[14]  J. Bissler,et al.  Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review , 2016, Therapeutic advances in urology.

[15]  F. Trepiccione,et al.  Renal Atp6ap2/(Pro)renin Receptor Is Required for Normal Vacuolar H+-ATPase Function but Not for the Renin-Angiotensin System. , 2016, Journal of the American Society of Nephrology : JASN.

[16]  M. Brucker,et al.  The Past and the Future. , 2016, Nursing for women's health.

[17]  E. Thiele,et al.  Tuberous Sclerosis Complex , 2019, Harper's Textbook of Pediatric Dermatology.

[18]  E. Roach,et al.  Tuberous sclerosis complex. , 2015, Handbook of clinical neurology.

[19]  L. Lagae,et al.  Tuberous sclerosis complex: the past and the future , 2015, Pediatric Nephrology.

[20]  S. Grinstein,et al.  The vacuolar-type H+-ATPase at a glance – more than a proton pump , 2014, Journal of Cell Science.

[21]  Tetsuhiro Tanaka,et al.  ANO1: an additional key player in cyst growth. , 2014, Kidney international.

[22]  Cuilan Yang,et al.  Activation of mTORC1 in collecting ducts causes hyperkalemia. , 2014, Journal of the American Society of Nephrology : JASN.

[23]  R. Rasooly,et al.  Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop. , 2014, American journal of physiology. Renal physiology.

[24]  M. Soleimani,et al.  Double Knockout of Carbonic Anhydrase II (CAII) and Na+-Cl- Cotransporter (NCC) Causes Salt Wasting and Volume Depletion , 2013, Cellular Physiology and Biochemistry.

[25]  Dennis Brown,et al.  Regulation of luminal acidification by the V-ATPase. , 2013, Physiology.

[26]  B. Manning,et al.  Signal integration by mTORC1 coordinates nutrient input with biosynthetic output , 2013, Nature Cell Biology.

[27]  David Chen,et al.  Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[28]  M. Bader,et al.  (Pro)renin receptor: subcellular localizations and functions. , 2013, Frontiers in bioscience.

[29]  E. Hoorn,et al.  Key developments in renin–angiotensin–aldosterone system inhibition , 2013, Nature Reviews Nephrology.

[30]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[31]  M. Soleimani,et al.  Slc26a11, a chloride transporter, localizes with the vacuolar H(+)-ATPase of A-intercalated cells of the kidney. , 2011, Kidney international.

[32]  Roberto Zoncu,et al.  mTORC1 Senses Lysosomal Amino Acids Through an Inside-Out Mechanism That Requires the Vacuolar H+-ATPase , 2011, Science.

[33]  D. Corey,et al.  Regulation of TFEB and V-ATPases by mTORC1 , 2011, The EMBO journal.

[34]  B. Viollet,et al.  AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 , 2011, Nature Cell Biology.

[35]  Paul Landais,et al.  Extended Report , 2022 .

[36]  J. Bissler,et al.  Tuberous Sclerosis Complex Renal Disease , 2010, Nephron Experimental Nephrology.

[37]  Y. Kong,et al.  Inactivation of Notch signaling in the renal collecting duct causes nephrogenic diabetes insipidus in mice. , 2009, The Journal of clinical investigation.

[38]  B. Rutkowski,et al.  Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. , 2009, Transplantation proceedings.

[39]  T. Schüpbach,et al.  The vacuolar proton pump, V-ATPase, is required for notch signaling and endosomal trafficking in Drosophila. , 2009, Developmental cell.

[40]  O. Devuyst,et al.  Regulated acid–base transport in the collecting duct , 2009, Pflügers Archiv - European Journal of Physiology.

[41]  Sylvie Breton,et al.  The Forkhead Transcription Factor Foxi1 Is a Master Regulator of Vacuolar H+-ATPase Proton Pump Subunits in the Inner Ear, Kidney and Epididymis , 2009, PloS one.

[42]  L. Cantley,et al.  Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. , 2008, Human molecular genetics.

[43]  Vincent J Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[44]  Michael Forgac,et al.  Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology , 2007, Nature Reviews Molecular Cell Biology.

[45]  K. Guan,et al.  Expanding mTOR signaling , 2007, Cell Research.

[46]  S. Petrovic,et al.  Chloride/bicarbonate exchanger SLC26A7 is localized in endosomes in medullary collecting duct cells and is targeted to the basolateral membrane in hypertonicity and potassium depletion. , 2006, Journal of the American Society of Nephrology : JASN.

[47]  J. Bissler,et al.  Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  P. Courtoy,et al.  Ubiquitous and kidney-specific subunits of vacuolar H+-ATPase are differentially expressed during nephrogenesis. , 2005, Journal of the American Society of Nephrology : JASN.

[49]  D. Kwiatkowski,et al.  Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. , 2005, Human molecular genetics.

[50]  J. Avruch,et al.  Rheb Binding to Mammalian Target of Rapamycin (mTOR) Is Regulated by Amino Acid Sufficiency* , 2005, Journal of Biological Chemistry.

[51]  U. Kornak,et al.  Vacuolar H+-ATPase d2 subunit: molecular characterization, developmental regulation, and localization to specialized proton pumps in kidney and bone. , 2005, Journal of the American Society of Nephrology : JASN.

[52]  D. Kwiatkowski,et al.  A mouse model of cardiac rhabdomyoma generated by loss of Tsc1 in ventricular myocytes. , 2005, Human molecular genetics.

[53]  E. Hafen,et al.  Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. , 2004, Genes & development.

[54]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[55]  G. Schwartz,et al.  A fork in the road of cell differentiation in the kidney tubule. , 2004, The Journal of clinical investigation.

[56]  G. Bergström,et al.  Distal renal tubular acidosis in mice that lack the forkhead transcription factor Foxi1. , 2004, The Journal of clinical investigation.

[57]  J. Blenis,et al.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression , 2004, Oncogene.

[58]  G. Schwartz,et al.  Distal renal tubular acidosis , 2004, Current opinion in pediatrics.

[59]  K. Inoki,et al.  Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. , 2003, Genes & development.

[60]  J. Blenis,et al.  Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. , 2002, Genes & development.

[61]  J. Frøkiaer,et al.  Aquaporins in the kidney: from molecules to medicine. , 2002, Physiological reviews.

[62]  M. Soleimani,et al.  Fasting downregulates renal water channel AQP2 and causes polyuria. , 2001, American journal of physiology. Renal physiology.

[63]  J. Frøkiaer,et al.  Physiology and pathophysiology of renal aquaporins. , 1999, Journal of the American Society of Nephrology : JASN.

[64]  Thomas J. Jentsch,et al.  ClC-5 Cl--channel disruption impairs endocytosis in a mouse model for Dent's disease , 2000, Nature.

[65]  Tobias Schmelzle,et al.  TOR, a Central Controller of Cell Growth , 2000, Cell.

[66]  L. A. Haddad,et al.  Similarities and differences in the subcellular localization of hamartin and tuberin in the kidney. , 2000, American journal of physiology. Renal physiology.

[67]  H. Onda,et al.  Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. , 1999, The Journal of clinical investigation.

[68]  M. Yasui,et al.  Aquaporin-6: An intracellular vesicle water channel protein in renal epithelia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[69]  P. Courtoy,et al.  Intra-renal and subcellular distribution of the human chloride channel, CLC-5, reveals a pathophysiological basis for Dent's disease. , 1999, Human molecular genetics.

[70]  P. Stricklett,et al.  Targeting Collecting Tubules Using the Aquaporin-2 Promoter , 1999, Nephron Experimental Nephrology.

[71]  T. Jentsch,et al.  ClC-5, the chloride channel mutated in Dent's disease, colocalizes with the proton pump in endocytotically active kidney cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[72]  J. R. Bosqueiro,et al.  Role of Cl− in Electrogenic H+ Secretion by Cortical Distal Tubule , 1997, The Journal of Membrane Biology.

[73]  W. Sly,et al.  Depletion of intercalated cells from collecting ducts of carbonic anhydrase II-deficient (CAR2 null) mice. , 1995, The American journal of physiology.

[74]  P. Harris,et al.  The molecular genetics of tuberous sclerosis. , 1994, Human molecular genetics.

[75]  J. Rapola,et al.  Polycystic disease of the kidney. Evaluation and classification based on nephron segment and cell-type specific markers. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[76]  H. Lodish,et al.  Subtypes of intercalated cells in rat kidney collecting duct defined by antibodies against erythroid band 3 and renal vacuolar H+-ATPase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[77]  R. Erickson,et al.  N-ethyl-N-nitrosourea-induced null mutation at the mouse Car-2 locus: an animal model for human carbonic anhydrase II deficiency syndrome. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[78]  Robert C. Wolpert,et al.  A Review of the , 1985 .